赛隆药业集团股份有限公司关于子公司获得化学原料药上市申请批准通知书的公告

Group 1 - The company announced that its wholly-owned subsidiary, Hunan Sailong Pharmaceutical Co., Ltd., has received the approval notice for the listing application of the chemical raw material drug, Rabeprazole [1][2] - The approval notice includes details such as the registration number (Y20240000786), acceptance number (CYHS2460643), and the effective period of 12 months [1] - Rabeprazole injection is indicated for the treatment of gastric ulcers and duodenal ulcers when oral therapy is not suitable [2] Group 2 - The approval of Rabeprazole will further enrich the company's raw material drug product pipeline [3] - The production and sales situation will depend on various internal and external environmental changes, indicating a level of uncertainty [3] - The company commits to timely information disclosure based on subsequent developments [3]